Related references
Note: Only part of the references are listed.Combining Galantamine and Memantine in Multitargeted, New Chemical Entities Potentially Useful in Alzheimer's Disease
Elena Simoni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Mechanisms of Neuroprotective Effects of Nicotine and Acetylcholinesterase Inhibitors: Role of alpha 4 and alpha 7 Receptors in Neuroprotection
Akinori Akaike et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2010)
Memantine Preferentially Blocks Extrasynaptic over Synaptic NMDA Receptor Currents in Hippocampal Autapses
Peng Xia et al.
JOURNAL OF NEUROSCIENCE (2010)
Alzheimer's disease: strategies for disease modification
Martin Citron
NATURE REVIEWS DRUG DISCOVERY (2010)
Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons
Joana B. Melo et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2009)
Cognition-enhancing and anxiolytic effects of memantine
Rimante Minkeviciene et al.
NEUROPHARMACOLOGY (2008)
Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils
Silvia Lorrio et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats
C. Pieta Dias et al.
NEUROSCIENCE (2007)
NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo
Yitao Liu et al.
JOURNAL OF NEUROSCIENCE (2007)
In vitro galantamine-memantine co-application: Mechanism of beneficial action
Xilong Zhao et al.
NEUROPHARMACOLOGY (2006)
Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade
Yuki Takada-Takatori et al.
NEUROPHARMACOLOGY (2006)
Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial
Elaine R. Peskind et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2006)
Rationale for combination therapy with galantamine and Memantine in Alzheimer's disease
George T. Grossberg et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity
Christiane Volbracht et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons
CG Thomas et al.
JOURNAL OF NEUROPHYSIOLOGY (2006)
Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
SA Lipton
NATURE REVIEWS DRUG DISCOVERY (2006)
Protective effect of donepezil in primary-cultured rat cortical neurons exposed to N-methyl-D-aspartate (NMDA) toxicity
S Akasofu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
The chemical biology of clinically tolerated NMDA receptor antagonists
Huei-Sheng Vincent Chen et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Effects of memantine on behavioural symptoms in Alzheimer's disease patients:: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies
S Gauthier et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2005)
Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons
S Moriguchi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity
T Kihara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons
Y Takada et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors
M Samochocki et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Involvement of calcineurin in the neurotoxic effects induced by amyloid-beta and prion peptides
P Agostinho et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2003)
Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
A Maelicke et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Share Paper
